- Home
- AHG vs RIGL Comparison
AHG vs RIGL Comparison
Compare AHG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | RIGL |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.6M | 911.8M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AHG | RIGL |
|---|---|---|
| Price | $1.23 | $48.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $63.00 |
| AVG Volume (30 Days) | 102.3K | ★ 172.4K |
| Earning Date | 07-23-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $35.72 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $0.68 | $24.84 |
| 52 Week High | $2.50 | $52.24 |
Technical Indicators
Market Signals| Indicator | AHG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 50.18 |
| Support Level | $1.10 | $44.50 |
| Resistance Level | $1.53 | $50.19 |
| Average True Range (ATR) | 0.14 | 1.91 |
| MACD | 0.04 | -0.28 |
| Stochastic Oscillator | 81.46 | 36.63 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.